RAD is playing out to the 2013 prediction. Triple $ 3.20 price target.
I expect the debt refinancing to happen by the end of February swiftly followed by a Moody's upgrade,, followed by Feb sales that beat estimates and show continued prescription count growth.
I would be surprised if the stock didn't hit $2.50- $3 by mid March.
Sentiment: Strong Buy
Yaa baby. Shorts for your own good just start covering.